Skip to main content
. Author manuscript; available in PMC: 2010 Oct 12.
Published in final edited form as: Clin Endocrinol (Oxf). 2008 Jan 25;69(2):292–298. doi: 10.1111/j.1365-2265.2008.03201.x

Table 2.

Comparison between patients and healthy controls

Patients (n = 38)
GH-deficient (50%) GH-sufficient (50%) Controls (n = 22)
Gender 6 males/13 females 2 males/17 females 5 males/17 females
Age (years) 45·4 ± 7·6 46·3 ± 10·0 45·6 ± 12·4
BMI (kg/m2) 36·2 ± 9·2 30·5 ± 5·0* 28·8 ± 7·3**
Tumour size (mm) 4·3 ± 1·9 4·0 ± 1·9 –
Serum IGF-1 (nmol/ l) 13·2 ± 3·0 15·4 ± 3·7 15·7 ± 4·6
IGF-1 SDS −1·52 ± 0·45 −1·16 ± 0·52* −0·93 ± 0·53***
No. of patients with other pituitary hormone deficits
  1/TSH 10 5
  2/ACTH 1 0
  3/LH/FSH 7 3

Data are presented as mean ± SD.

*

P < 0·05 vs. GH-deficient patients;

**

P < 0·01 vs. GH-deficient patients;

***

P < 0·001 vs. GH-deficient patients.